Preventive stRategy for IMMU132-relatED AEs in TNBC - PRIMED
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|Breast Cancer
Interventions: DRUG: Sacituzumab govitecan|DRUG: Loperamide|DRUG: Granulocyte Colony-Stimulating Factor
Sponsor: MedSIR
Collaborators: Gilead Sciences